Convicted Cocaine Money Launderer Emerges as Influential Player in Illinois Cannabis Industry
In a striking case involving the cannabis industry, David Berger, a convicted felon found guilty of federal money-laundering charges, remains licensed to operate in Illinois’ legal marijuana market. Berger, 42, was implicated in a scheme to launder money for a Mexican cocaine-trafficking ring, yet he continues to manage multiple dispensaries under the Ivy Hall brand. […]
Texas Stores Prepare for Final Sale of Smokeable Hemp Cannabis as Deadline Approaches
On March 30, 2026, the day before Texas implemented a ban on smokeable hemp-derived THCA products, customers flocked to Happy Clouds smoke shop in Austin. Among them was Huey Ellis, who purchased these products in anticipation of the approaching regulations. Final Moments Before the Ban Shortly after his purchase, Ellis posed for a portrait, aware […]
Texas Retailers Bid Farewell to Smokeable Hemp Cannabis as Deadline Approaches
On March 30, 2026, Huey Ellis purchased smokeable hemp-derived THCA products at Happy Clouds smoke shop in Austin, Texas, just one day before the state enacted a ban on such sales. This prohibition significantly impacts consumers relying on these products for various uses. Following his purchase, Ellis posed for a portrait, reflecting a moment that […]
Top Cannabis Companies to Work For in 2026 Unveiled: Meet the Industry Leaders
This year marks the seventh consecutive Cannabis Business Times “Best Cannabis Companies to Work For” program. Honoring companies on this year’s list is essential, as they have successfully navigated numerous industry challenges to create environments where employees thrive. These awards celebrate their noteworthy achievements. The 2026 “Best Cannabis Companies to Work For” list includes firms […]
Washington State’s Clinical Snapshot Reveals Health Issues Linked to Cannabis Use – UW Medicine Report
A recent survey of nearly 400 clinicians in Washington state revealed significant concerns regarding the mental health risks associated with cannabis use. Over half of the respondents reported observing cannabis-related adverse health events in their patients, with nearly 20% witnessing such incidents two to three times each month. These findings were published in the Substance […]
White House Plans Weekly Meetings to Discuss FDA Cannabis Product Enforcement Policy
The White House has scheduled four meetings with cannabis industry and research stakeholders this week to discuss a proposed enforcement policy regarding CBD products. The Office of Information and Regulatory Affairs (OIRA), part of the White House Office of Management and Budget (OMB), announced plans to review a yet-to-be-published guidance titled “Cannabidiol (CBD) Products Compliance […]
New Minnesota Cannabis Regulations Spark Diverse Reactions Among Medical, Recreational, and Hemp Operators
Minnesota lawmakers are currently considering significant changes to cannabis and hemp business regulations that could influence the pricing and availability of cannabis products across the state. The proposals are under scrutiny as they aim to ease operational challenges for businesses spanning medical, recreational, and hemp markets while addressing supply shortages. Proposed Changes and Industry Impact […]
Survey Reveals Over Half of Washington Clinicians Concerned About Mental Health Risks from Cannabis Use
SEATTLE — Over a decade after the legalization of recreational cannabis in Washington, a recent survey indicates that many health professionals are increasingly concerned about the mental health risks associated with cannabis use. Some clinicians report that they are regularly treating patients with cannabis-related health issues. The findings, published in the Substance Use & Addiction […]
Rescheduling Cannabis Under the Controlled Substances Act: A Transformative Step for Legalization and Research
Experts are examining the path to and implications of rescheduling cannabis. In a recent executive order, President Donald J. Trump directed the Attorney General to proceed with rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA). This shift underscores the need for federal support to enhance research into medical marijuana […]